Our results showed that patients with low levels of sPD-L1 at baseline had the highest rates of both OS and PFS, suggesting that sPD-L1 represents a prognostic factor for survival outcome in cancer patients treated with immunotherapy (Figure 6). Here, SPDL1 is linked to cancer.